Dabigatran Versus Warfarin After Mitral and Aortic Bioprosthesis Replacement for the Management of Atrial Fibrillation Postoperatively: Pilot Study

Trial Profile

Dabigatran Versus Warfarin After Mitral and Aortic Bioprosthesis Replacement for the Management of Atrial Fibrillation Postoperatively: Pilot Study

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 18 Feb 2016

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Warfarin
  • Indications Stroke; Thromboembolism
  • Focus Therapeutic Use
  • Acronyms DAWA
  • Most Recent Events

    • 18 Feb 2016 Primary endpoint has not been met. (Intracardiac Thrombus), as per results published in the Drugs in R and D.
    • 18 Feb 2016 Results published in the Drugs in R and D
    • 08 Oct 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top